cbdMD Diversifies Beyond Hemp with Twinlab Acquisition
Charlotte, Monday, 2 November 2026.
Facing cannabis industry headwinds, cbdMD finalized its distressed asset takeover of legacy supplement maker Twinlab on November 2, absorbing $30 million in trailing revenue to enter mainstream retail channels.
A Strategic Pivot Amid Cannabis Headwinds
Publicly traded wellness company cbdMD, Inc. (NYSE American: YCBD) completed its acquisition of Twinlab’s operating assets and established brands—including Twinlab, Reserveage, Metabolife, and ResVitale—on November 2, 2026 [1][3]. The distressed-asset purchase, executed through a Florida Chapter 727 assignment for the benefit of creditors proceeding, positions cbdMD to diversify its business beyond hemp-derived cannabidiol products [1][3]. This strategic move comes as the company seeks to mitigate regulatory uncertainty in the cannabis sector while expanding into mainstream dietary supplements, anti-aging, and functional wellness markets [1][3].
Legacy Brands Join a Portfolio of Growth
The acquisition adds four established brands—Twinlab, Reserveage, Metabolife, and ResVitale—to cbdMD’s existing portfolio, which already includes cbdMD, Paw CBD, Oasis, and Bluebird Botanicals [1][3]. Twinlab, founded in the 1960s, is one of the most recognizable names in American wellness, while Metabolife was once a billion-dollar weight-loss brand, and Reserveage commands significant consumer recognition in the anti-aging space [1]. Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD, emphasized the strategic value of the deal, stating, ‘Together with our existing brands, we believe we have a portfolio that runs from the fundamentals to the frontier of wellness, built around one promise: More Life in Every Day’ [1].
Financial Scale and Future Integration Plans
The combined trailing twelve-month revenue for the acquired Twinlab-related brands up to June 2026 was approximately US$30 million [3]. cbdMD has signaled plans to introduce new products and refreshed brand experiences across the expanded portfolio over the coming months, with further integration details expected in upcoming periodic reports and earnings communications [1][3]. The acquisition was executed as a distressed asset purchase, subject to court approval, reflecting the insolvency process of the seller rather than a traditional going-concern transaction [3].
Broader Industry Context: Brand Consolidation in Wellness
The Twinlab acquisition fits into a broader trend of consolidation within the wellness and consumer health sectors. Taylor Sicard’s The Index, updated on November 1, 2026, tracks 1,212 direct-to-consumer brands and their ownership structures, highlighting the increasing role of strategic brand owners, asset-light licensing holdcos, and private-equity platforms in reshaping the market [3]. For example, Unilever acquired the supplement brand Gruns for approximately US$1.2 billion in April 2026, while Procter & Gamble agreed to buy Thorne from L Catterton for US$3.8 billion in August 2026, pending close [3]. These transactions underscore the competitive pressure within the wellness space, where established players are leveraging acquisitions to diversify revenue streams and capture market share [3].
Regulatory Uncertainty and the Cannabis Conundrum
cbdMD’s diversification strategy is particularly timely given the regulatory volatility surrounding hemp-derived products. Kennedy noted that the acquisition ‘diversifies our business beyond hemp at a time of regulatory uncertainty in that category,’ signaling a deliberate shift toward more stable and mainstream markets [1]. While cbdMD’s core offerings in CBD remain a significant part of its business, the addition of Twinlab and its associated brands provides a hedge against potential disruptions in the cannabis industry [1][3].
What’s Next for cbdMD and Its New Brands
Looking ahead, cbdMD plans to leverage its brand-building expertise to drive growth across the expanded portfolio. Kennedy highlighted Twinlab’s ‘long-standing reputation for quality’ and expressed enthusiasm for bringing ‘our brand-building experience to its next chapter of growth’ [1]. As the company integrates these legacy brands into its operations, industry observers will be watching closely to see how cbdMD balances innovation with the preservation of the heritage and equity of the acquired brands [1][3].